Table 1 Associations of hsa-miR-7 with CDR1-AS and clinical parameters in the prognostic patient cohort.

Parameters	n	CDR1-AS		hsa-mir-7
Parameters	n	median expression [IQR]	P	median expression [IQR]	P
All patients	345	4.97 [8.74]		0.034 [0.053]
*hsa-miR-7* expression
1st quantile (low)	173	7.16 [10.02]
2nd quantile (high)	172	3.52 [6.78]	<*0.001*
Age at time of surgery (years)
≤40	38	3.37 [8.88]		0.039 [0.044]
>40-≤55	134	5.09 [7.84]		0.032 [0.057]
>55-≤70	117	5.65 [9.04]		0.033 [0.050]
>70	56	4.46 [8.26]	0.37	0.047 [0.063]	0.58
Menopausal status
Premenopausal	153	4.69 [8.31]		0.033 [0.057]
Postmenopausal	192	5.19 [8.90]	0.84	0.035 [0.057]	0.74
Pathological tumour size
pT1	161	6.95 [9.31]		0.029 [0.042]
pT2+ unknown	171	3.97 [7.14]		0.037 [0.066]
pT3+ pT4	13	3.66 [13.7]	*0.013*	0.055 [0.032]	*0.024*
Tumour grade
Poor	197	4.72 [8.07]		0.043 [0.062]
Unknown	95	3.58 [7.87]		0.033 [0.051]
Moderate/Good	53	8.63 [7.87]	*0.001*	0.023 [0.027]	<*0.001*
Tumour cell content
30–70%	230	6.10 [9.38]		0.033 [0.053]
>70%	115	3.48 [7.78]	<*0.001*	0.042 [0.061]	0.08
Hormone receptor/growth factor status (RT-qPCR)*
ESR1-negative	120	4.21 [7.84]		0.046 [0.062]
ESR1-positive	225	5.41 [8.92]	0.10	0.030 [0.047]	*0.007*
PGR-negative	158	4.21 [7.84]		0.046 [0.066]
PGR-positive	187	5.41 [9.47]	0.08	0.028 [0.045]	<*0.001*
ERBB2-non-amplified	294	5.49 [9.07]		0.033 [0.054]
ERBB2-amplified	51	3.97 [6.17]	0.22	0.039 [0.059]	0.43
EGFR quantile 1 (low)	115	2.84 [4.85]		0.042 [0.062]
EGFR quantile 2 (in between)	116	7.61 [9.61]		0.031 [0.059]
EGFR quantile 3 (high)	114	6.24 [10.12]	<*0.001*	0.032 [0.046]	*0.042*

For the analysis on the association between hsa-miR-7 expression and CDR1-AS expression, patients were divided into two equally sized groups based on median hsa-miR-7 expression level. Next to this analysis result, the associations of the clinical parameters with hsa-miR-7 and CDR1-AS gene expression are listed. The median CDR1-AS and hsa-miR-7 expression levels per subcategory, including the interquartile range (IQR) are given additionally. Pathological tumour size is defined as follows: pT1 < = 2 cm, pT2 > 2 cm and < = 5 cm, pT3 > 5 cm, and pT4 = tumour with direct extension to chest wall and/or skin. *Cut-offs for positive and negative hormone receptor/growth factor status established as previously described^56,57. P = p-value and n = number of patients. Significant p-values are printed in bold.

Search